# CRISPR-Cas9 In Vivo Gene Editing offor Hereditary Angioedema

- **DOI:** [10.1056/nejmoa2309149](https://doi.org/10.1056/nejmoa2309149)
- **Rating:** Sound (3.7 out of 5)
- **Verdict:** First-in-human KLKB1 editing delivers clear pharmacodynamic activity and encouraging short-term safety, but the uncontrolled ten-patient design cannot establish clinical efficacy.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-09-18
- **Evaluation page:** https://www.nabu.science/paper/10.1056%2Fnejmoa2309149

## Key claims

1. a single dose of NTLA-2002 led to robust, dose-dependent, and durable reductions in total plasma kallikrein levels, and no severe adverse events were observed
   - Support: Supported
   - Type: Primary finding
   - Basis: objective pharmacodynamic changes and observed short-term safety in only ten patients with unequal follow-up
   - Location: Abstract, Conclusions
2. The mean percentage change in the number of angioedema attacks per month from baseline through the latest assessment was -95%
   - Support: Tentative
   - Type: Secondary
   - Basis: uncontrolled open-label attack assessment with concomitant prophylaxis and only nine patients contributing percentage changes
   - Location: Abstract, Results; Table 3
3. Patients who discontinued concomitant long-term prophylaxis continued to have well-controlled disease
   - Support: Supported
   - Type: Secondary
   - Basis: descriptive post-withdrawal observations in six patients without randomized withdrawal or a concurrent control
   - Location: Discussion, p. 438; Figure 2

## Strengths

- **Novel human evidence for KLKB1 editing** The study extends systemic in vivo CRISPR-Cas9 treatment to a new target and disease, demonstrating sustained dose-dependent reductions in total plasma kallikrein.
  - Dimension: contribution
  - Location: Results, Pharmacodynamics; Figure 1
- **Systematic early-phase safety assessment** Adverse events were graded using CTCAE v5.0, with laboratory, electrocardiographic, immunogenicity, and dose-limiting-toxicity monitoring reported across all treated patients.
  - Dimension: methodological rigour
  - Location: Methods, Clinical Assessments and Study End Points; Results, Safety; Table 2
- **Limitations inform the next trial** The Discussion connects absent placebo control, concomitant prophylaxis, ascertainment differences, and limited follow-up to uncertainty, then explains how phase 2 washout and randomization address attribution.
  - Dimension: positioning
  - Location: Discussion, pp. 439–440

## Limitations

- **Clinical efficacy remains uncontrolled and subjective** Attack reductions come from an open-label, single-group study using electronic diaries and unblinded investigator confirmation, leaving expectation, ascertainment, and temporal effects unresolved.
  - Dimension: methodological rigour
  - Location: Methods, Study Design and Oversight and Clinical Assessments
- **Concomitant prophylaxis complicates treatment attribution** Six patients continued long-term prophylaxis after dosing, and withdrawal timing was chosen by investigators and patients. Post-withdrawal attack freedom is informative but does not isolate the treatment effect.
  - Dimension: methodological rigour
  - Location: Results, Angioedema Attacks; Figure 2; Discussion, pp. 439–440
- **Tiny homogeneous cohort limits generalization** Only ten adults were treated, all identified as White, with follow-up varying by dose cohort. Safety, efficacy, and transferability therefore remain uncertain beyond this narrow sample.
  - Dimension: application pathway
  - Location: Results, Patients; Table 1

## Reliability checks

Caveats (4 of 4 checks).

- **Internal coherence:** Noted. The principal numerical results are internally consistent, and the paper explicitly reports the absence of a clinical dose-response in attacks. Interpretation of the exploratory attack reductions remains sensitive to ascertainment differences and concomitant prophylaxis.
- **Research conduct:** Clean. Ethics approval, written consent, independent monitoring, prospective registration, sponsor funding, disclosures, and a data-sharing statement are declared. No location-referenced conduct failure was identified in the supplied text.
- **Reference integrity:** Clean. 17 of 17 checkable references verified
  - 17 references in manuscript
  - 1 reference confirmed by manual review
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17